Transgenomic Said Q4 Revenue Fell 4-Percent as Losses, R&D Spending Shrank

genomeweb
360dx

Transgenomic Said Q4 Revenue Fell 4-Percent as Losses, R&D Spending Shrank

Apr 01, 2005

NEW YORK, April 1 (GenomeWeb News) - Transgenomic yesterday reported that fourth-quarter revenue fell 4 percent as R&D spending declined and net losses narrowed.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

People in the News: Feng Deng, Laurence Klotz, Jerry Williamson
In Brief This Week: ACT Genomics, Rosetta Genomics, Abbott, and More
FDA Approves Abbott CDx, Agios Drug for AML Patients With IDH1 Mutation
CRISPR Interference Platform Maps Genetic Interactions on Large Scale
New Products Posted to GenomeWeb: Swift Biosciences, MNG Laboratories, AMS Biotechnology
Studies Explore Genetic Alterations Linked to Aggressive, Metastatic Prostate Cancer

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Main menu